Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro

Drug Metabolism and Disposition

Volumn 33, Issue 11, 2005, Pages 1580-1583

  Weiss, Johanna ^a   Sauer, Alexandra ^a   Frank, Andreas ^b   Unger, Matthias ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEMETHOXYYANGONIN; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; GLYCOPROTEIN P INHIBITOR; KAVA EXTRACT; KAWAIN; LACTONE DERIVATIVE; METHYSTICIN; QUINIDINE; YANGONIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG POTENCY; DRUG SOLUBILITY; FLUORESCENCE; LIPOPHILICITY; MEDICINAL PLANT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ANXIETY AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCEINS; KAVA; LACTONES; LEUKEMIA P388; MICE; P-GLYCOPROTEIN; PLANT EXTRACTS; PLANT ROOTS; PYRONES; TRANSFECTION;

ANIMALIA; PIPER METHYSTICUM;

EID: 27544501065     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.005892     Document Type: Article

References (28)

1. Anke J and Ramzan I (2004a) Pharmacokinetic and pharmacodynamic drug interactions with kava (Piper methysticum Forst. f.). J Ethnopharmacol 93:153-160.
2. Anke J and Ramzan I (2004b) Kava hepatotoxicity: are we any closer to the truth? Planta Med 70:193-196.
3. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, and Fromm MF (2002) Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302:645-650.
4. Boesch D, Gaveriaux C, Jachez, B Pourtier-Manzane-Do A, Bollinger P, and Loor F (1991) In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51:4226-4233.
5. Choi JS, Choi HK, and Shin SC (2004) Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 275:165-170.
6. Clouatre DL (2004) Kava kava: examining new reports of toxicity. Toxicol Lett 150:85-96.
7. Côté CS, Kor C, Cohen J, and Auclair K (2004) Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 322:147-157.
8. Dresser GK, Schwarz UI, Wilkinson GR, and Kim RB (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 73:41-50.
9. Fröhlich M, Albermann S, Sauer A, Walter-Sack I, Haefeli WE, and Weiss J (2004) In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochem Pharmacol 68:2409-2416.
10. Gurley BJ, Gardner SF, Hubbard M, Williams DK, Brooks Gentry W, Khan IA, and Shah A (2005) In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1 and 3A4/5 phenotypes. Clin Pharmacol Ther 77:415-426.
11. Ioannides C (2002) Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32:451-478.
12. Izzo AA (2004) Drug interactions with St. John's Wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42:139-148.
13. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
14. Martin-Facklam M, Rieger K, Riedel K-D, Burhenne J, Walter-Sack I, and Haefeli WE (2004) Undeclared exposure of St. John's wort in hospitalized patients. Br J Clin Pharm 58:437-441.
15. Rengelshausen J, Banfield M, Riedel K-D, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli WE, and Mikus G (2005) Opposite effects of acute and chronic St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 78:25-33.
16. Russmann S, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K, and Wenk M (2005) Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther 77:453-454.
17. Schinkel AH and Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3-29.
18. Singh YN and Singh NN (2002) Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16:731-743.
19. Tarbah F, Mahler H, Kardel B, Weinmann W, Hafner D, and Daldrup T (2003) Kinetics of kavain and its metabolites after oral application. J Chromatogr B 789:115-130.
20. Teschke R, Gaus W, and Loew D (2003) Kava extracts: safety and risks including rare hepatoxicity. Phytomedicine 10:440-446.
21. Unger M and Frank A (2004) Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 18:2273-2281.
22. Unger M, Holzgrabe U, Jacobsen W, Cummins C, and Benet LZ (2002) Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 68:1055-1058.
23. Wang EJ, Barecki-Roach M, and Johnson WW (2004) Quantitative characterization of direct P-glycoprotein inhibition by St. John's wort constituents hypericin and hyperforin. J Pharm Pharmacol 56:123-128.
24. Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, and Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197-204.
25. Whitton PA, Lau A, Salisbury A, Whitehouse J, and Evans CS (2003) Kava lactones and the kava-kava controversy. Phytochemistry 64:673-679.
26. Zhou S, Lim LY, and Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57-104.
27. Zou L, Harkey MR, and Henderson GL (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71:1579-1589.
28. Zou L, Henderson GL, Harkey MR, Sakai Y, and Li A (2004) Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 11:285-294.